Clinical effect of itraconazole oral solutions on pulmonary candidiasis albicans in ICU patients
- VernacularTitle:口服伊曲康唑治疗危重患者白色念珠菌肺部感染临床疗效观察
- Author:
Jian LI
;
Wenxiu CHANG
;
Keliang CUI
- Publication Type:Journal Article
- Keywords:
Itraconazole;
ICU;
Candida Albicans;
Fluconazole
- From:
Chinese Journal of Practical Internal Medicine
2006;0(24):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical effect of itraconazole oral solutions on pulmonary candidiasis albicans in ICU patients.Methods A total of 71 patients with candida ablicans in their sputum clutures were randomized into two groups.The itraconazole group(n= 36)received itraconazole 200 mg,p.o.(including nasal feeding),q12h for 14 days.The fluconazole group(n=35)received fluconazole 400 mg for the first dose,then 200 mg,i.v.drip,qd for 14 days.Results There were 31 patients in the itraconazole group and 29 paitents in the fluconazole group who completed their treatment.In the itraconazole and fluconazole group,the clearance of candida ablicans was 64.52%(20/31)vs.65.55%(19/29),cleaning time(10.12?2.57)vs(8.87?1.95)days,effective rate 58.06%(18/31)vs 62.07%(18/29),recovery rate is 19.35%(6/31)vs 17.24%(5/29),occurrence of hepatic dysfunction is 25.81%(8/31)vs 24.14%(7/29),and withdrawal for inefficacy was 3.23%(1/31)vs 6.90%(2/29),respectively.These parameters did not have statistical significance.Conclusion Itraconazole oral solutions can be used effectively and safely in the treatment of pulmonary candidiasis albicans in ICU.Patients with renal dysfunction do not need to adjust the dosage.
